Skip to main content
Publications
Anthony MS , Aroda VR, Parlett LE, Djebarri L, Berreghis S, Calingaert B , Beachler DC, Crowe CL, Johannes CB , Juhaeri J, Lanes S, Pan C, Rothman KJ , Saltus CW , Walsh KE. Risk of anaphylaxis among new users of glp-1 receptor agonists: a cohort study . Diabetes Care. 2024 Apr 1;47(4):712-9. doi: 10.2337/dc23-1911
Hageman SHJ, Pennells L, Pajouheshnia R , Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, van der Schouw YT, Verschuren WMM, Lehmann N, Jockel KH, Di Angelantonio E, Visseren FLJ, Dorresteijn JAN. The value of additional risk factors for improving 10-year cardiovascular risk prediction in apparently healthy people . Poster presented at the European Society for Cardiology Congress 2022; August 26, 2022. Barcelona, Spain. [abstract] Eur Heart J. 2022 Oct 3; 43(Supple 2):16. doi: 10.1093/eurheartj/ehac544.2277
Hageman SHJ, Pennells L, Pajouheshnia R , Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, van der Schouw YT, Verschuren WMM, Lehmann N, Jockel KH, Di Angelantonio E, Visseren FLJ, Dorresteijn JAN. The value of additional risk factors for improving 10-year cardiovascular risk prediction in apparently healthy people . Poster presented at the ESC Congress 2022; August 26, 2022. Barcelona, Spain. [abstract] Eur Heart J. 2022 Oct 3; 43(Suppl 2). doi: 10.1093/eurheartj/ehac544.2277
Lip GYH, Diener H-C, Dubner SJ, Halperin JL, Rothman KJ , Ma C-S, Lu S, Paquette M, Riou Franca L, Zint K, Teutsch C, Huisman MV. Treatment persistence of patients with atrial fibrillation on VKA or NOAC: data from GLORIA-AF Phase III 1-year interim analysis . Poster presented at the 2019 ESC Congress; August 2019. Paris, France. [abstract] Eur Heart J. 2019 Oct 21; 40(Supplement 1):ehz745.11. doi: 10.1093/eurheartj/ehz745.1159
Heritier H, Vienneau D, Foraster M , Eze IC, Schaffner E, de Hoogh K, Thiesse L, Rudzik F, Habermacher M, Kopfli M, Pieren R, Brink M, Cajochen C, Wunderli JM, Probst-Hensch N, Roosli M. A systematic analysis of mutual effects of transportation noise and air pollution exposure on myocardial infarction mortality: a nationwide cohort study in Switzerland . Eur Heart J. 2019 Feb 14;40(7):598-603. doi: 10.1093/eurheartj/ehy650
MacDonald TM, Hawkey CJ, Ford I, McMurray JJV, Scheiman JM, Hallas J, Findlay E, Grobbee DE, Hobbs FDR, Ralston SH, Reid DM, Walters MR, Webster J, Ruschitzka F, Ritchie SLD, Perez-Gutthann S , Connolly E, Greenlaw N, Wilson A, Wei L, Mackenzie IS. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT) . Eur Heart J. 2017 Jun 14;38(23):1843-50. doi: 10.1093/eurheartj/ehw387
Yosipovitch G, Reaney M, Mastey V, Eckert L, Nelson L , Clark M , Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis . Poster presented at the 2017 American Academy of Dermatology Annual Meeting; March 4, 2017. Orlando, FL. [abstract] J Am Acad Dermatol. 2017 Jun; 76(6 Suppl 1):AB278. doi: 10.1016/j.jaad.2017.04.1082
Strober B, Gottlieb AB, Sherif B , Mollon P, Gilloteau I, McLeod L , Fox T, Mordin M , Gnanasakthy A , Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept . J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Fuks KB, Weinmayr G, Basagana X, Gruzieva O, Hampel R, Oftedal B, Sorensen M, Wolf K, Aamodt G, Aasvang GM, Aguilera I, Becker T, Beelen R, Brunekreef B, Caracciolo B, Cyrys J, Elosua R, Eriksen KR, Foraster M , Fratiglioni L, Hilding A, Houthuijs D, Korek m, Kunzli N, Marrugat J, Nieuwenhuijsen M, Ostenson C-G, Penell J, Pershagen G, Raaschou-Nielsen O, Swart WJR, Peters A, Hoffmann B. Long-term exposure to ambient air pollution and traffic noise and incident hypertension in seven cohorts of the European study of cohorts for air pollution effects (ESCAPE) . Eur Heart J. 2016 Oct 24;38(13):983-90. doi: 10.1093/eurheartj/ehw413
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1054
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of-life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5[S1]):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1053
Kimball AB, Rothman KJ , Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results . J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050
Pladevall-Vila M , Singal B, Williams LK, Brotons C, Guyer H, Sadurni J, Falces C, Serrano-Rios M, Gabriel R, Shaw JE, Zimmet PZ, Haffner S. A single factor underlies the metabolic syndrome: a confirmatory factor analysis . Diabetes Care. 2006 Jan;29(1):113-22.
Dhamrait SS, Payne JR, Li P, Jones A, Toor IS, Cooper JA, Hawe E , Palmen JM, Wootton PT, Miller GT, Humphries SE, Montgomery HE. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension . Eur Heart J. 2003;24(18):1672-80.